trending Market Intelligence /marketintelligence/en/news-insights/trending/tw5yj3qz_6zjhbactwsp5a2 content esgSubNav
In This List

Alkermes submits application to US FDA for depression treatment

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Alkermes submits application to US FDA for depression treatment

Alkermes plc submitted a new drug application to the U.S. Food and Drug Administration for ALKS 5461 as an adjunctive treatment of major depressive disorder.

Major depressive disorder is a condition in which patients exhibit depressive symptoms in daily activities consistently for at least a two-week period and demonstrate impaired social, occupational, educational or other important functioning.

An adjunct therapy is another treatment used together with the primary treatment.

ALKS 5461 was granted fast-track status by the FDA in October 2013 for the same treatment usage in patients with an inadequate response to standard antidepressant therapies.

The application is based on a comprehensive clinical efficacy and safety package with data from more than 30 clinical trials involving patients with the disorder.